Compass Therapeutics (CMPX) Non Operating Income (2019 - 2026)

Compass Therapeutics' Non Operating Income history runs 8 years deep, the most recent figure standing at $2.0 million for Q1 2026.

• In Q1 2026, Non Operating Income rose 48.69% year-over-year to $2.0 million; the TTM figure through Mar 2026 stood at $7.0 million (up 6.03% YoY), while the FY2025 annual figure was $6.4 million, down 12.41% from the prior year.
• Non Operating Income came in at $2.0 million for Q1 2026 at Compass Therapeutics, down from $2.3 million in the prior quarter.
• In the past five years, Non Operating Income ranged from a high of $2.3 million in Q4 2025 to a low of $20000.0 in Q1 2022.
• A 5-year average of $1.5 million and a median of $1.8 million in 2024 frame the typical range for Non Operating Income.
• Across the five-year window, Non Operating Income surged 18385.71% in 2022 and sank 39.82% in 2025, its largest moves.
• Compass Therapeutics' Non Operating Income stood at $1.3 million in 2022, then soared by 52.86% to $2.0 million in 2023, then dropped by 22.09% to $1.5 million in 2024, then jumped by 47.57% to $2.3 million in 2025, then dropped by 12.84% to $2.0 million in 2026.
• According to Business Quant data, Non Operating Income over the past three periods registered $2.0 million, $2.3 million, and $1.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison